Best Penny Stocks For Your July 2021 List? 8 Biotechs To Watch Now
Current & former penny stocks to watch if you like biotech right now.
The post Best Penny Stocks For Your July 2021 List? 8 Biotechs To Watch Now appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
These Current & Former Biotech Penny Stocks Have Seen A Strong Year So Far
One of the great things about biotech penny stocks is the potential of these companies. There are very few places that offer this kind of early access to potentially life-saving treatments. If you take a look at last year’s pandemic, some of the most unassuming names flourished. That was thanks to the fast-acting business acumen from some of these companies. One of the biggest highlights, at least among penny stock traders, was Novavax (NASDAQ: NVAX).
This was one of the biggest winners of the pandemic, thanks to a quick pivot in treatment focus. The company was working on an influenza treatment when coronavirus cases began picking up. It was then that the company started to flip things around. Fast-forward about a year, and NVAX stock went from under $5 to over $330 thanks to key milestones reached in its vaccine treatment candidate.
Biotech Industry Trends Attract Investors
Something else to note is that big investment continues flooding this industry. Look back at where large positions (via 13F filings) were built. Biotech has stood out for years. According to data from WhaleWisdom, Sector Allocation has clearly shown an overwhelming trend in favor of Health Care related companies:
I think you’ll see the trend I’m talking about above. The green bars represent 13F allocation over time, being very strong in Health Care. Institutional investment managers file 13Fs each quarter. These investors exercise investment discretion over at least $100 million in 13F securities. So this is where you’ll hear about “whales” being in stocks as it refers to larger investors. Why health care and biotech?
Hot Biotech Stocks To Watch
Not only do companies have the potential to achieve what Novavax was able to under the right circumstances, but the industry is also full of big mergers and acquisitions. Early-stage companies develop clinical trial pipelines. Larger companies may then target these smaller firms as buyout candidates.
For instance, Merck (NYSE: MRK) bought cancer drug research company VelosBio Inc. from Pappas Capital and other investors for $2.75 billion. Gilead Sciences (NASDAQ: GILD) picked up Immunomedics for $21 billion to gain access to a breast cancer treatment, Trodelvy. The list goes on. In this article, we’ll look at a few current and former biotech penny stocks that have continued demonstrating strength in the stock market in 2021.
Biotech Stocks To Watch: GT Biopharma Inc. (NASDAQ: GTBP)
Taking a look at stock charts first, GT Biopharma has seen a strong year in the market. Less than 52 weeks ago, the former penny stock was trading around $2 a share. An uplist to the NASDAQ earlier this year and several key milestones have helped bring some added attention to the company. GT Biopharma focuses on advancing its immune treatment pipeline. The backbone to this pipeline is its tri-specific killer engager technology or “TriKE” treatment. Its solid tumor TriKEs are designed to target breast, lung, gastric, colorectal, and ovarian cancer indications.
The main point of focus for the market right now is on the company’s lead treatment candidate GTB-3550. It’s currently undergoing clinical trials in a Phase 1/2 study in patients with acute myeloid leukemia (AML) and higher-risk myelodysplastic syndrome (HR MDS). In a recent update, the company presented interim data on GTB-3550 at the Raymond James Human Health Innovation Conference.
“We have seen significant reductions in CD33+ cancer cells in four of the last seven patients (57%) treated with doses of GTB-3550 ranging from 25mcg/kg/day to 150mcg/kg/day. This early sign of CD33+ target-specific cancer cell killing is very encouraging as we begin to focus on transitioning to the expanded efficacy part of the current GTB-3550 clinical trial.”
Anthony Cataldo, GT Biopharma Chairman and Chief Executive Officer
Furthermore, analysts at B.Riley recently raised their price target to $26 on GTBP stock. This was thanks, in part, to preclinical prostate cancer treatment showing meaningful response to TriKE combined with FT538, a Fate Therapeutics natural killer cell treatment. This week could be another important one for the company as it attends the Sir Anthony Ritossa Global Family Office Investment Summit.
Second Sight Medical Products (NASDAQ: EYES)
Shares of Second Sight have also experienced a strong move over the last year. Despite being down from their 2021 highs, EYES stock has climbed from under $1 to over $5 over the last 52 weeks. Company growth and sector momentum bolstered this trend. The company develops implantable visual prosthetics. The company recently closed a $57.5 million offer to put toward developing its Orion device, among other things. This is the company’s cortical stimulation device providing artificial vision to visually impaired patients.
Are large investors watching EYES stock right now? When we discussed large investors earlier, it’s important to focus on quarterly 13Fs and other things like 13Ds. Certain investors with larger positions periodically file statements like these. In the case of Second Sight, Empery Asset Management recently reported an 8.71% stake in the company.
Biotech Penny Stocks To Watch: Daré Bioscience Inc. (NASDAQ: DARE)
Daré is one of the current biotech penny stocks gaining steam in the market this week. It came in tandem with the company’s presentation on Phase 1 results of its DARE-HRT1 treatment. This is the company’s intravaginal ring (IVR) designed for delivering bio-identical hormone therapy. The treatment targets patients with vasomotor symptoms and genitourinary syndrome associated with menopause.
“We are highly encouraged by these Phase 1 data as they demonstrate DARE-HRT1’s ability to achieve our dual release objectives,” said David Friend, Ph.D., Chief Scientific Officer of Daré Bioscience. “In addition to delivering hormone therapy, we believe the IVR technology used in DARE-HRT1 is an important platform technology with the potential to offer a versatile, vaginal drug delivery solution to address a variety of unmet needs in women’s health through its ability to release one or more drugs at desired rates over time and with the added benefit of convenience.”
What’s more, this week, Roth Capital helped give DARE stock a boost. The firm maintained its Buy rating on the penny stock. However, analysts boosted their $9 price target to $11.
Predictive Oncology Inc. (NASDAQ: POAI)
Another one of the biotech penny stocks jumping this week is Predictive Oncology. The company focuses on artificial intelligence for applications in oncology and drug discovery. Earlier this month, the company announced that two of its subsidiaries expanded their services by completing the build-out and qualification of GMP labs. Furthermore, the facilities are expected to increase the potential customer base and enhance the potential for longer-term collaborations.
Further to this, Predictive got a nice boost on June 30th, thanks to new analyst coverage from H.C. Wainwright. The firm started Predictive with a Buy rating along with a $5 price target.
More Biotech Penny Stocks To Watch
While these are some of the more active names, there are plenty more biotech penny stocks that could be on the watch list right now. Other trending names in the stock market today include:
Heading into the new month, quarter, and half of the year, they’ve all been trending as biotech and healthcare captivate investor interest in 2021.
Pursuant to an agreement between Midam Ventures LLC and GT Biopharma (GTBP) Midam has been paid $150,000 for a period from March 1, 2021, to April 1, 2021. This compensation is payment 1 of 12 as part of a 12-month agreement between Midam Ventures LLC & GT Biopharma (GTBP), for a period from March 1, 2021, to February 28, 2022. Midam Ventures LLC expects to be paid $150,000 per month for a total of 12 months by GT Biopharma (GTBP). Midam has been paid an additional $150,000 for a period from April 2, 2021, to May 1, 2021. This compensation is payment 2 of 12 as part of the Agreement. Midam has been paid an additional $150,000 for a period from May 2, 2021, to June 1, 2021. This compensation is payment 3 of 12 as part of the Agreement. Midam has been paid an additional $150,000 for a period from June 2, 2021, to July 1, 2021. This compensation is payment 4 of 12 as part of the Agreement. We may buy or sell additional shares of GT Biopharma (GTBP) in the open market at any time, including before, during, or after the Website and Information, to provide public dissemination of favorable Information about GT Biopharma (GTBP). Click Here For Full Disclaimer.
BUFFALO, NY- March 11, 2024 – Impact Journals publishes scholarly journals in the biomedical sciences with a focus on all areas of cancer and aging research. Aging is one of the most prominent journals published by Impact Journals.
Credit: Impact Journals
BUFFALO, NY- March 11, 2024 – Impact Journals publishes scholarly journals in the biomedical sciences with a focus on all areas of cancer and aging research. Aging is one of the most prominent journals published by Impact Journals.
Impact Journals will be participating as an exhibitor at the American Association for Cancer Research (AACR) Annual Meeting 2024 from April 5-10 at the San Diego Convention Center in San Diego, California. This year, the AACR meeting theme is “Inspiring Science • Fueling Progress • Revolutionizing Care.”
Visit booth #4159 at the AACR Annual Meeting 2024 to connect with members of the Agingteam.
About Aging-US:
Agingpublishes research papers in all fields of aging research including but not limited, aging from yeast to mammals, cellular senescence, age-related diseases such as cancer and Alzheimer’s diseases and their prevention and treatment, anti-aging strategies and drug development and especially the role of signal transduction pathways such as mTOR in aging and potential approaches to modulate these signaling pathways to extend lifespan. The journal aims to promote treatment of age-related diseases by slowing down aging, validation of anti-aging drugs by treating age-related diseases, prevention of cancer by inhibiting aging. Cancer and COVID-19 are age-related diseases.
Agingis indexed and archived byPubMed/Medline (abbreviated as “Aging (Albany NY)”), PubMed Central, Web of Science: Science Citation Index Expanded (abbreviated as “Aging‐US” and listed in the Cell Biology and Geriatrics & Gerontology categories), Scopus (abbreviated as “Aging” and listed in the Cell Biology and Aging categories), Biological Abstracts, BIOSIS Previews, EMBASE, META (Chan Zuckerberg Initiative) (2018-2022), and Dimensions (Digital Science).
Please visit our website at www.Aging-US.com and connect with us:
Mathematicians use AI to identify emerging COVID-19 variants
Scientists at The Universities of Manchester and Oxford have developed an AI framework that can identify and track new and concerning COVID-19 variants…
Scientists at The Universities of Manchester and Oxford have developed an AI framework that can identify and track new and concerning COVID-19 variants and could help with other infections in the future.
Scientists at The Universities of Manchester and Oxford have developed an AI framework that can identify and track new and concerning COVID-19 variants and could help with other infections in the future.
The framework combines dimension reduction techniques and a new explainable clustering algorithm called CLASSIX, developed by mathematicians at The University of Manchester. This enables the quick identification of groups of viral genomes that might present a risk in the future from huge volumes of data.
The study, presented this week in the journal PNAS, could support traditional methods of tracking viral evolution, such as phylogenetic analysis, which currently require extensive manual curation.
Roberto Cahuantzi, a researcher at The University of Manchester and first and corresponding author of the paper, said: “Since the emergence of COVID-19, we have seen multiple waves of new variants, heightened transmissibility, evasion of immune responses, and increased severity of illness.
“Scientists are now intensifying efforts to pinpoint these worrying new variants, such as alpha, delta and omicron, at the earliest stages of their emergence. If we can find a way to do this quickly and efficiently, it will enable us to be more proactive in our response, such as tailored vaccine development and may even enable us to eliminate the variants before they become established.”
Like many other RNA viruses, COVID-19 has a high mutation rate and short time between generations meaning it evolves extremely rapidly. This means identifying new strains that are likely to be problematic in the future requires considerable effort.
Currently, there are almost 16 million sequences available on the GISAID database (the Global Initiative on Sharing All Influenza Data), which provides access to genomic data of influenza viruses.
Mapping the evolution and history of all COVID-19 genomes from this data is currently done using extremely large amounts of computer and human time.
The described method allows automation of such tasks. The researchers processed 5.7 million high-coverage sequences in only one to two days on a standard modern laptop; this would not be possible for existing methods, putting identification of concerning pathogen strains in the hands of more researchers due to reduced resource needs.
Thomas House, Professor of Mathematical Sciences at The University of Manchester, said: “The unprecedented amount of genetic data generated during the pandemic demands improvements to our methods to analyse it thoroughly. The data is continuing to grow rapidly but without showing a benefit to curating this data, there is a risk that it will be removed or deleted.
“We know that human expert time is limited, so our approach should not replace the work of humans all together but work alongside them to enable the job to be done much quicker and free our experts for other vital developments.”
The proposed method works by breaking down genetic sequences of the COVID-19 virus into smaller “words” (called 3-mers) represented as numbers by counting them. Then, it groups similar sequences together based on their word patterns using machine learning techniques.
Stefan Güttel, Professor of Applied Mathematics at the University of Manchester, said: “The clustering algorithm CLASSIX we developed is much less computationally demanding than traditional methods and is fully explainable, meaning that it provides textual and visual explanations of the computed clusters.”
Roberto Cahuantzi added: “Our analysis serves as a proof of concept, demonstrating the potential use of machine learning methods as an alert tool for the early discovery of emerging major variants without relying on the need to generate phylogenies.
“Whilst phylogenetics remains the ‘gold standard’ for understanding the viral ancestry, these machine learning methods can accommodate several orders of magnitude more sequences than the current phylogenetic methods and at a low computational cost.”
Journal
Proceedings of the National Academy of Sciences
DOI
10.1073/pnas.2317284121
Article Title
Unsupervised identification of significant lineages of SARS-CoV-2 through scalable machine learning methods
While the size of the United States makes it hard for it to compete with the inter-city train access available in places like Japan and many European countries, Amtrak trains are a very popular transportation option in certain pockets of the country — so much so that the country’s national railway company is expanding its Northeast Corridor by more than one million seats.
Running from Boston all the way south to Washington, D.C., the route is one of the most popular as it passes through the most densely populated part of the country and serves as a commuter train for those who need to go between East Coast cities such as New York and Philadelphia for business.
Veronika Bondarenko captured this photo of New York’s Moynihan Train Hall.
Veronika Bondarenko
Amtrak launches new routes, promises travelers ‘additional travel options’
Earlier this month, Amtrak announced that it was adding four additional Northeastern routes to its schedule — two more routes between New York’s Penn Station and Union Station in Washington, D.C. on the weekend, a new early-morning weekday route between New York and Philadelphia’s William H. Gray III 30th Street Station and a weekend route between Philadelphia and Boston’s South Station.
According to Amtrak, these additions will increase Northeast Corridor’s service by 20% on the weekdays and 10% on the weekends for a total of one million additional seats when counted by how many will ride the corridor over the year.
“More people are taking the train than ever before and we’re proud to offer our customers additional travel options when they ride with us on the Northeast Regional,” Amtrak Executive Vice President and Chief Commercial Officer Eliot Hamlisch said in a statement on the new routes. “The Northeast Regional gets you where you want to go comfortably, conveniently and sustainably as you breeze past traffic on I-95 for a more enjoyable travel experience.”
Here are some of the other Amtrak changes you can expect to see
Amtrak also said that, in the 2023 financial year, the Northeast Corridor had nearly 9.2 million riders — 8% more than it had pre-pandemic and a 29% increase from 2022. The higher demand, particularly during both off-peak hours and the time when many business travelers use to get to work, is pushing Amtrak to invest into this corridor in particular.
To reach more customers, Amtrak has also made several changes to both its routes and pricing system. In the fall of 2023, it introduced a type of new “Night Owl Fare” — if traveling during very late or very early hours, one can go between cities like New York and Philadelphia or Philadelphia and Washington. D.C. for $5 to $15.
As travel on the same routes during peak hours can reach as much as $300, this was a deliberate move to reach those who have the flexibility of time and might have otherwise preferred more affordable methods of transportation such as the bus. After seeing strong uptake, Amtrak added this type of fare to more Boston routes.
The largest distances, such as the ones between Boston and New York or New York and Washington, are available at the lowest rate for $20.
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.
This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
Necessary cookies are absolutely essential for the website to function properly. These cookies ensure basic functionalities and security features of the website, anonymously.
Cookie
Duration
Description
cookielawinfo-checbox-analytics
11 months
This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checbox-functional
11 months
The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checbox-others
11 months
This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-necessary
11 months
This cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-performance
11 months
This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
viewed_cookie_policy
11 months
The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
Functional cookies help to perform certain functionalities like sharing the content of the website on social media platforms, collect feedbacks, and other third-party features.
Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.
Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics the number of visitors, bounce rate, traffic source, etc.
Advertisement cookies are used to provide visitors with relevant ads and marketing campaigns. These cookies track visitors across websites and collect information to provide customized ads.
